Biomedpharma

Biomed Pharma is a privately-owned Canadian pharmaceutical company headquartered in Montreal, Quebec. Established in 2002 as Biomed2002, the company initially focused on distributing generic drugs across Quebec. In 2014, it rebranded to Biomed Pharma to reflect its expanded vision and growth ambitions. By 2017, under new leadership, Biomed Pharma aimed to optimize its growth in the evolving pharmaceutical landscape by maintaining exceptional customer service and fostering innovation. (biomed-pharma.ca)

Biomed Pharma specializes in importing and marketing a diverse portfolio of pharmaceutical products, including high-volume generics, branded medications, biosimilars, and both prescription and over-the-counter natural health products. The company is committed to expanding its product range through strategic acquisitions and partnerships with global suppliers, ensuring the availability of high-quality products to meet the needs of the Canadian market. (biomed-pharma.ca)

Biomed Pharma's distribution network is centered in Quebec, with its headquarters located at 1B-9450, boulevard Langelier, Saint-Léonard, Quebec, Canada. The company serves pharmacies across Quebec, reflecting its regional focus. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, Biomed Pharma emphasizes a personalized approach to customer service, supported by a flexible administrative structure and a dynamic team. (biomed-pharma.ca)

Biomed Pharma operates primarily as a pharmaceutical importer and distributor within Canada's supply chain. By importing a range of pharmaceutical products, including generics, branded medications, and biosimilars, the company plays a crucial role in ensuring the availability of diverse therapeutic options to meet the needs of Canadian healthcare providers and patients. (biomed-pharma.ca)

Biomed Pharma's sourcing strategy exhibits a high degree of concentration, with all 20 shipments from India sourced exclusively from INTAS Pharmaceuticals Limited, amounting to a total import value of $1.0 million USD. This single-source dependency may present risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the consistent sourcing from INTAS Pharmaceuticals Limited suggests a stable and reliable relationship, potentially mitigating some of these risks. The company's focus on a limited number of products—Atorvastatin and Calcium—further underscores this concentrated sourcing approach.

Biomed Pharma's supply chain resilience appears limited due to its exclusive reliance on INTAS Pharmaceuticals Limited for imports from India. The lack of backup suppliers and the narrow product range imported from India may expose the company to significant risks in the event of supply chain disruptions. Additionally, the absence of publicly available information regarding the regulatory compliance of INTAS Pharmaceuticals Limited and the diversity of shipping routes further highlights potential vulnerabilities in the supply chain.

Biomed Pharma's concentrated sourcing strategy positions the company to benefit from strong supplier relationships and potentially favorable terms with INTAS Pharmaceuticals Limited. However, this approach also exposes the company to risks associated with supply chain disruptions and regulatory changes affecting the supplier. For Indian exporters seeking to become alternative suppliers, diversifying the product portfolio and establishing robust supply chain capabilities could present opportunities to meet Biomed Pharma's needs and mitigate the risks associated with its current sourcing strategy.

In Canada, the importation and sale of pharmaceutical products are regulated by Health Canada under the Food and Drugs Act and its associated Regulations. This framework ensures that all drugs, including prescription and over-the-counter medications, biologics, and natural health products, meet rigorous standards for safety, efficacy, and quality before they are authorized for sale in the Canadian market. (canada.ca)

To import pharmaceutical products into Canada, companies must obtain an Establishment Licence (EL) from Health Canada, authorizing them to import specific categories of drugs. Additionally, each drug product must have a Drug Identification Number (DIN) assigned by Health Canada, indicating that the product has been reviewed and authorized for sale in Canada. Importers are also required to ensure that their foreign manufacturing sites comply with Good Manufacturing Practice (GMP) standards recognized by Health Canada, such as those from the European Union (EU GMP), World Health Organization (WHO GMP), or Pharmaceutical Inspection Co-operation Scheme (PIC/S). (canada.ca)

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Canadian standards. Stability requirements ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in both English and French, providing clear information on dosage, administration, and potential side effects. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market. (canada.ca)

Between 2024 and 2026, Health Canada implemented several policy changes affecting the importation of pharmaceutical products, including updates to the Exceptional Importation and Sale framework to address drug shortages. These changes introduced new requirements for the importation and sale of foreign-authorized drugs, emphasizing the need for compliance with GMP standards and other regulatory criteria. Importers must stay informed about these regulatory updates to ensure continued compliance and uninterrupted access to essential pharmaceutical products. (canada.ca)

Biomed Pharma's focus on importing Atorvastatin and Calcium indicates a strategic emphasis on high-demand cardiovascular medications and essential supplements. The significant import value of Atorvastatin suggests a strong market demand for cholesterol-lowering therapies, while the importation of Calcium reflects a commitment to providing essential nutrients to the Canadian population. This product strategy aligns with the company's mission to offer a diversified portfolio of pharmaceutical products and services to meet the needs of healthcare professionals and patients. (biomed-pharma.ca)

Biomed Pharma's sourcing strategy is characterized by a focus on generic drugs, with a particular emphasis on formulations such as tablets, capsules, syrups, and injections. The company's exclusive reliance on INTAS Pharmaceuticals Limited for imports from India suggests a strategic choice to maintain a stable and reliable supply chain. However, this concentrated sourcing approach may limit the company's ability to diversify its product offerings and mitigate risks associated with supply chain disruptions.

Based on its product mix, Biomed Pharma primarily serves the retail pharmacy segment in Canada, supplying essential medications and supplements to community pharmacies across Quebec. The company's focus on high-demand products like Atorvastatin and Calcium positions it as a key supplier of cardiovascular and nutritional therapies, catering to the needs of both healthcare professionals and patients. (biomed-pharma.ca)

There is a realistic opportunity for new Indian suppliers to collaborate with Biomed Pharma by offering a diversified range of pharmaceutical products that align with the company's focus on high-quality generics and essential medications. By meeting Health Canada's regulatory requirements and demonstrating compliance with recognized GMP standards, Indian exporters can position themselves as viable partners to support Biomed Pharma's mission to expand its product portfolio and address unmet needs in the Canadian market. (canada.ca)

Indian exporters seeking to supply Biomed Pharma must ensure that their products are authorized for sale in Canada, possessing a valid Drug Identification Number (DIN) issued by Health Canada. Manufacturing sites must comply with GMP standards recognized by Health Canada, such as EU GMP, WHO GMP, or PIC/S. Additionally, exporters must provide comprehensive product information, including monographs, labeling in both English and French, and evidence of compliance with Canadian regulatory requirements. (canada.ca)

Indian exporters interested in supplying Biomed Pharma should initiate contact through the company's "Business Proposal" form available on their website. It is advisable to participate in industry events, such as the DCAT Week 2026 in New York, where Biomed Pharma is actively seeking new collaborations. Understanding and adhering to Health Canada's import regulations, including obtaining the necessary licenses and ensuring GMP compliance, is crucial. Establishing a clear communication channel and demonstrating a commitment to quality and regulatory compliance will facilitate the development of a successful partnership.